Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Profitability
This table compares Nektar Therapeutics and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -284.18% | -85.40% | -39.99% |
| Journey Medical | -14.82% | -35.57% | -10.88% |
Earnings and Valuation
This table compares Nektar Therapeutics and Journey Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nektar Therapeutics | $55.63 million | 38.65 | -$164.08 million | ($8.42) | -7.56 |
| Journey Medical | $61.86 million | 2.95 | -$11.43 million | ($0.37) | -17.89 |
Journey Medical has higher revenue and earnings than Nektar Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Nektar Therapeutics and Journey Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
Nektar Therapeutics currently has a consensus target price of $149.63, indicating a potential upside of 135.07%. Journey Medical has a consensus target price of $13.00, indicating a potential upside of 96.37%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Journey Medical.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
